BIAF Insider Trading Activity and SEC Form 4 Filings
BIAF insider trading summary
No open-market insider purchases or sales of bioAffinity Technologies, Inc. (BIAF) have been reported on SEC Form 4 in the past 12 months.
Latest BIAF insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 1, 2022 | James Michael Edwards | Chief Financial Officer | Buy | $0 (2,448 @ $0.00) |
| Aug 31, 2022 | Stuart Diamond | Director | Buy | $0 (4,081 @ $0.00) |
| Aug 31, 2022 | Robert A. Anderson | Director | Buy | $0 (4,081 @ $0.00) |
| Aug 31, 2022 | Peter S Knight | Director | Buy | $0 (8,163 @ $0.00) |
| Aug 31, 2022 | Gary D Rubin | Director | Buy | $0 (16,326 @ $0.00) |
| Aug 31, 2022 | Harvey Sandler Revocable Trust | 10% Owner | Buy | $0 (16,326 @ $0.00) |
| Aug 31, 2022 | Steven Girgenti | Executive Chairman | Buy | $0 (40,916 @ $0.00) |
| Aug 31, 2022 | Maria Zannes | President, CEO | Buy | $0 (16,326 @ $0.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.